Pharma

Your Article Summary

See Latest Articles

Merck warned by FDA over vaccine plant failings
Corporate News Releases - The Healthcare Sales & Marketing Network, 05/08/08

The agency said Merck had filed an 'inadequate response" to a Form 483 sent to the company several weeks ago, and it now needed to see immediate corrective action. The agency highlighted several areas in which the plant deviated from good manufacturing practices (GMP). For example, Merck is accused of not investigating why some batches of product were outside of specifications, as well as "failure to maintain production and process control," according to the FDA.

Today in Drug/Product Approvals...keeping you current

Receive free subspecialty "5-minute updates" via email

FDA Approves Boston Scientifics Express LD Iliac Stent System
Boston Scientific, 03/12/10

FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer
Watson Pharmaceuticals, 03/12/10

Abbott Seeks FDA Approval of a New Six-Month 45-mg Formulation of Lupron Depot for the Palliative Treatment of Advanced Prostate Cancer
Abbott, 03/12/10

 See all of Drug/Product Approvals

Today in Regulatory Issues...keeping you current

Receive free subspecialty "5-minute updates" via email

McKesson's McCall Gets 10 Years
HealthDataManagement, 03/12/10

KAPIDEX (dexlansoprazole) Renamed DEXILANT in U.S. to Avoid Name Confusion
Takeda Pharmaceuticals North America, 03/05/10

Teva Announces Favorable Court Ruling in Generic Hyzaar® and Cozaar® Litigation
Teva Pharmaceutical Industries, 03/03/10

 See all of Regulatory Issues